Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPOX | P50336 | 4/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13064242 | 0.88 | ALDH1A1 (0.46) | PPOXKDM4AKDM5AKDM2BKDM4C | |
| SCHEMBL9610123 | 0.84 | KDM4A (0.40) | KDM4AKDM5AKDM2BKDM4CKDM5B | |
| SCHEMBL859530 | 0.79 | PPOX (0.39) | PPOXALDH1A1L3MBTL1GLALMNA | |
| SCHEMBL9610129 | 0.79 | KDM5A (0.45) | KDM4AKDM5AKDM2BKDM4CKDM5B | |
| SCHEMBL846807 | 0.71 | PDE2A (0.36) | PPOXALDH1A1GLACYP3A4MAPT | |
| SCHEMBL861475 | 0.70 | POLB (0.44) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL9610084 | 0.67 | BCHE (0.37) | KDM4AKDM5AKDM2BKDM4CKDM5B | |
| SCHEMBL860225 | 0.67 | HSD11B1 (0.52) | ALDH1A1CYP3A4HSD11B1MEN1KMT2A | |
| SCHEMBL19386035 | 0.66 | NPC1 (0.47) | ALDH1A1L3MBTL1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL9610096 | 0.65 | BCHE (0.37) | KDM4AKDM5AKDM2BKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | XDH, PON1, OAT | PPOX 1717/4885KDM4A 3190/4885KDM5A 2705/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | PPOX 3881/4885KDM4A 1612/4885KDM5A 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.